Monitor for any upcoming corporate events (earnings, trial data, or regulatory decisions) that may have prompted the coordinated selling. The uniform pricing and C-suite participation suggest a pre-arranged plan, but the concentration of sales by the CEO and COO warrants attention. If no negative catalyst emerges, the selling is likely routine diversification.
Price Chart
Executive Summary
Seven insiders at Crescent BioPharma, including CEO Joshua Brumm and President/COO Jonathan McNeill, sold shares on June 22, 2026, totaling $1.23 million. The sales represent 0.26% of market cap and occurred at a uniform price of $17.99, suggesting a pre-arranged plan. While the cluster is notable for involving top executives, the modest dollar amount relative to market cap and the weak predictive power of insider sales limit the bearish signal.
Key Financial Metrics
Key Facts
- CEO Joshua Brumm sold 42,300 shares for $761,000.
- President/COO Jonathan McNeill sold 20,500 shares for $370,000.
- Total insider sales of $1.23 million represent 0.26% of CBIO's $471 million market cap.
- All seven insiders sold at the same price ($17.99) on the same day, consistent with a 10b5-1 plan.
- Recent 30-day insider activity shows 7 sells totaling $1.2 million, indicating this cluster is part of a broader pattern.
Financial Impact
Insider sales of $1.23 million, modest relative to market cap.
Risk Factors
- Potential negative catalyst if insider sales precede adverse news.
- Over-interpretation of routine 10b5-1 plan sales.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CBIO-1783025061814 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 8-K | $11.84 | awaiting T+60 | — | $13.27 (+12.08%) |
Oct 15, 2026 12d ago | Press Release | $11.84 | awaiting T+60 | — | $13.27 (+12.08%) |
Oct 5, 2026 22d ago | Press Release | $13.94 | awaiting T+60 | — | $13.27 (−4.81%) |
Sep 18, 2026 5w ago | Insider Cluster | $16.25 | awaiting T+60 | — | $13.27 (−18.34%) |
Jul 30, 2026 12w ago | 8-K | $15.02 $12.82 | ▼ −14.65% | ▼ −17.11% | $13.27 (−11.65%) |
Jul 20, 2026 14w ago | Insider Buy | $16.64 $12.91 | ▼ −22.42% | ▼ −26.39% | $13.27 (−20.25%) |
Jul 15, 2026 14w ago | 8-K / 424B5 | $15.11 $14.91 | ▲ +1.32% | ▲ +5.03% | $13.27 (+12.18%) |
Jul 14, 2026 15w ago | Press Release | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $13.27 (+15.32%) |
Jul 14, 2026 15w ago | 424B5 | $15.67 $14.12 | ▲ +9.89% | ▲ +12.42% | $13.27 (+15.32%) |
Jul 13, 2026 15w ago | EFFECT | $15.69 $13.57 | ▼ −13.51% | ▼ −17.51% | $13.27 (−15.42%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers